Ohara Pharmaceutical
Tokyo, Japan· Est.
Japanese pharma company developing innovative and generic drugs for oncology, hepatology, and CNS disorders.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Japanese pharma company developing innovative and generic drugs for oncology, hepatology, and CNS disorders.
OncologyHepatologyNeurologyMetabolic Disorders
Technology Platform
Multi-modality platform encompassing small molecules, recombinant proteins, and monoclonal antibodies with focus on pediatric cancers and hepatobiliary diseases.
Opportunities
Growth through orphan drug designations in Japan, expansion of biologic portfolio beyond small molecules, and strategic investments in African healthcare infrastructure for market expansion.
Risk Factors
Dependence on Japanese regulatory approvals, competition in generic drug markets, and execution risks in international expansion efforts.
Competitive Landscape
Competes with both large pharma in innovative therapies and generic manufacturers in established markets, differentiated by specialized focus on pediatric oncology and hepatology with hybrid business model.